Home › Therapeutic areas › Neurology › Schizophrenia
Schizophrenia (7 companies)
Companies with an active program in Schizophrenia.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $6.96B | 15 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.36B | 3 |
| MPLT | MapLight Therapeutics | Neurology | 1 | Phase 2 | $385M | 6 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 1 | Phase 1 | $19.3M | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+2 Rare | 1 | Phase 3 | $4.8M | 10 |
| TGTX | Tg Therapeutics | Neurology Rare | 1 | Approved | $9.16B | 6 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 3 | Approved | $231M | 27 |
No companies match.